Table 2.
Available meta-analyses evaluating temporary ovarian suppression with GnRHa during chemotherapy specifically and only in breast cancer patients.
| Authors | Year | Disease | No. of Included Studies (no. of RCTs) |
No. of Patients | Overall Results |
|---|---|---|---|---|---|
| Yang et al. [79] | 2013 | Breast cancer | 5 (5) | 528 | Protection for POI (not for pregnancy) |
| Wang et al. [80] | 2013 | Breast cancer | 7 (7) | 677 | Protection for POI |
| Vitek et al. [81] | 2014 | Breast cancer hormone receptor-negative only |
4 (4) | 252 | No protection |
| Shen et al. [82] | 2015 | Breast cancer | 11 (11) | 1062 | Protection for POI (not for pregnancy) |
| Lambertini et al. [83] | 2015 | Breast cancer | 12 (12) | 1231 | Protection for POI (also for pregnancy) |
| Munhoz et al. [84] | 2016 | Breast cancer | 7 (7) | 856 | Protection for POI (also for pregnancy) |
| Silva et al. [85] | 2016 | Breast cancer | 7 (7) a | 1002 a | Protection for POI |
| Bai et al. [86] | 2017 | Breast cancer | 15 (15) a | 1540 a | Protection for POI (also for pregnancy) |
| Lambertini et al. [87] | 2018 | Breast cancer | 5 (5) b | 873 | Protection for POI (also for pregnancy) |
Abbreviations: GnRHa: gonadotropin-releasing hormone agonist; POI: premature ovarian insufficiency; RCT: randomized controlled trial. a Data from the original publication (Del Mastro et al. JAMA 2011) and the updated analysis (Lambertini M et al. JAMA 2015) of the PROMISE-GIM6 trial were considered twice instead of as from the same study. b Based on individual patient-level data.